| Product Name | Ascrinvacumab ELISA Kit |
|---|---|
| Synonyms | PF-03446962, , CAS: 1463459-96-2 |
| Method | Quantitative |
| Detection Range | 0.31-5 μg/mL |
| Sensitivity | 0.156 μg/ml |
| Sample Types | Plasma, Serum |
| Reconstitution | Detection method: Colorimetric. Recovery: 80-120%. Specifications: Ascrinvacumab |
| Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Notes | Detection method: Colorimetric. Recovery: 80-120% |
| Background | Ascrinvacumab, also known as PF-03446962 or anti-hALK1 antibody, is a human immunoglobulin G (IgG) 2 monoclonal antibody which can be used as therapeutic antibody drug for the treatment of many tumors. It has been found that the clinical trials of ascrinvacumab has been developed in cancers including advanced solid tumors, urothelial cell carcinoma, hepatocellular carcinoma, and mesothelioma. Ascrinvacumab can binding to ACVRL1 by recognizing the extracellular domain of ACVRL1. ACVRL1, also called activin receptor-like kinase 1 (ALK1), is a transforming growth factor β (TGF-β) type I receptor. Ascrinvacumab is a fully human monoclonal antibody generated by immunizing the IgG 2 transgenic XenoMouse. In a human/mouse chimera tumor model, ascrinvacumab decreased human vessel density and improved antitumor efficacy when combined with bevacizumab (anti-VEGF). It suggests that ascrinvacumab therapy may be complementary to anti-VEGF in cancer intervention. As early as 2012, researchers had investigated the effects of ascrinvacumab on endothelial cell function. And the results showed that ascrinvacumab do interferes with the endothelial cell sprouting induced by Bone Morphogenetic Protein 9 (BMP9). A phase 2 trial study of ascrinvacumab in pre-treated patients with urothelial cancer had been reported in 2014. In addition, its treatment results of advanced solid tumors, hepatocellular carcinoma, and advanced malignant pleural mesothelioma also had been reported in 2016. In addition to advanced malignant pleural mesothelioma, ascrinvacumab shows the value of continuing treatment evaluation in the other two diseases. |
| Supplier | ARP |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
